Your browser doesn't support javascript.
loading
Emerging echinocandin-resistant Candida albicans and glabrata in Switzerland.
Coste, A T; Kritikos, A; Li, J; Khanna, N; Goldenberger, D; Garzoni, C; Zehnder, C; Boggian, K; Neofytos, D; Riat, A; Bachmann, D; Sanglard, D; Lamoth, F.
Afiliação
  • Coste AT; Institute of Microbiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
  • Kritikos A; Service of Infectious Diseases, Centre Hospitalier Universitaire Vaudois, Lausanne University Hospital and University of Lausanne, Rue du Bugnon 46, 1011, Lausanne, Switzerland.
  • Li J; Institute of Microbiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
  • Khanna N; Service of Infectious Diseases, Centre Hospitalier Universitaire Vaudois, Lausanne University Hospital and University of Lausanne, Rue du Bugnon 46, 1011, Lausanne, Switzerland.
  • Goldenberger D; Division of Infectious Diseases and Hospital Epidemiology, University and University Hospital of Basel, Basel, Switzerland.
  • Garzoni C; Division of Clinical Bacteriology and Mycology, University and University Hospital of Basel, Basel, Switzerland.
  • Zehnder C; Clinica Luganese Moncucco, Lugano, Switzerland.
  • Boggian K; SYNLAB Suisse SA, Bioggio, Switzerland.
  • Neofytos D; Division of Infectious Diseases and Hospital Epidemiology, Kantonsspital St.Gallen, St.Gallen, Switzerland.
  • Riat A; Service of Infectious Diseases, Geneva University Hospitals, Geneva, Switzerland.
  • Bachmann D; Service of Laboratory Medicine, Geneva University Hospitals, Geneva, Switzerland.
  • Sanglard D; Institute of Microbiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
  • Lamoth F; Institute of Microbiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Infection ; 48(5): 761-766, 2020 Oct.
Article em En | MEDLINE | ID: mdl-32661647
ABSTRACT
Echinocandins represent the first-line therapy of candidemia. Echinocandin resistance among Candida spp. is mainly due to acquired FKS mutations. In this study, we report the emergence of FKS-mutant Candida albicans/glabrata in Switzerland and provide the microbiological and clinical characteristics of 9 candidemic episodes. All patients were previously exposed to echinocandins (median 26 days; range 15-77). Five patients received initial echinocandin therapy with persistent candidemia in 4 of them. Overall mortality was 33%.
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Candida albicans / Farmacorresistência Fúngica / Candida glabrata / Equinocandinas / Candidemia / Antifúngicos Idioma: En Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Candida albicans / Farmacorresistência Fúngica / Candida glabrata / Equinocandinas / Candidemia / Antifúngicos Idioma: En Ano de publicação: 2020 Tipo de documento: Article